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Therapeutics for Treating Myocardial
Infarction and Peripheral Artery Disease
Melissa J. Hernandez, BS, Karen L. Christman, PHDCENTRAL ILLUSTRATION Acellular Biomaterial Therapeutics
for Repairing Ischemic Damage From MI and PAD
Hernandez, M.J. et al. J Am Coll Cardiol Basic Trans Science. 2017;2(2):212–26.
Preclinical studies have currently been investigating biomaterial-alone therapies or bio-
materials loaded with therapeutics as potential treatment options for myocardial infarction
(MI) and peripheral artery disease (PAD). Other therapeutics, like microribonucleic acids
(miRNAs) or exosomes, also show promise as factors to be delivered with a biomaterial.
However, the success of these therapies largely depends on satisfying specific design criteria.
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AB BAND ACRONYM S
bFGF = basic fibroblast growth
factor
CLI = critical limb ischemia
CVD = cardiovascular disease
ECM = extracellular matrix
FGF = fibroblast growth factor
HA = hyaluronic acid
HF = heart failure
HGF = hepatocyte growth
factor
LV = left ventricular
MI = myocardial infarction
miRNA = microribonucleic acid
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MaAs the number of global deaths attributed to cardiovascular disease continues to rise, viable treatments for
cardiovascular events such as myocardial infarction or conditions like peripheral artery disease are critical.
Recent studies investigating injectable biomaterials have shown promise in promoting tissue regeneration and
functional improvement, and in some cases, incorporating other therapeutics further augments the beneficial
effects of these biomaterials. In this review, we aim to emphasize the advantages of acellular injectable
biomaterial-based therapies, specifically material-alone approaches or delivery of acellular biologics, in regard
to manufacturability and the capacity of these biomaterials to regenerate or repair diseased tissue. We will
focus on design parameters and mechanisms that maximize therapeutic efficacy, particularly, improved
functional perfusion and neovascularization regarding peripheral artery disease and improved cardiac
function and reduced negative left ventricular remodeling post–myocardial infarction. We will then discuss
the rationale and challenges of designing new injectable biomaterial-based therapies for the clinic.
(J Am Coll Cardiol Basic Trans Science 2017;2:212–26) © 2017 Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
= peripheral artery
sePAD
diseaPCI = percutaneous coronary
intervention
VEGF = vascular endothelial
growth factorC ardiovascular disease (CVD) has long beenthe leading cause of death worldwide. In2013, CVD accounted for 31% of all deaths
(1), representing a 41.7% increase since 1990 (2). Of
the conditions classified as CVD, myocardial infarc-
tion (MI) and peripheral artery disease (PAD) are asso-
ciated with significant morbidity and mortality. In the
United States alone, approximately 8.5 million indi-
viduals are afflicted by PAD (3), and an estimated
660,000 individuals experience a new MI and
305,000 have a recurrent MI annually (4). The result-
ing negative left ventricular (LV) remodeling
and heart failure (HF) or critical limb ischemia (CLI)
and potential limb amputation that occurs in MI and
PAD patients, respectively, significantly reduces the
life expectancy of these individuals. Therefore, treat-
ments for repairing ischemic damage and restoring
muscle function for MI and PAD are needed.
Although current medical interventions mitigate
some symptoms, they fail to prevent HF post-MI or
remain unavailable for many patients with PAD. The
current gold standard for MI relies on percutaneous
coronary intervention (PCI) or a coronary artery
bypass graft to alleviate the occluded coronary artery.
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stenting and balloon angioplasty treat severe
conditions, but restenosis often occurs. In fact,
restenosis rates for stenting and balloon angioplasty
with optional stenting were both over 45% 2 years
after the initial intervention (5). Similar to MI pa-
tients, the extent of occlusions and resulting ischemic
damage fluctuates greatly among PAD patients,
ranging from intermittent claudication to CLI. This
variability contributes to difficulties with identifying
a widespread treatment, demonstrated by only
40% of individuals being eligible for existing
surgical procedures (6). Ultimately, new medical
interventions must be developed to overcome the
limitations of current approaches for MI and PAD.
Within the past 15 years, biomaterials have
emerged as a therapeutic approach to fill the existing
gaps in treatments for MI and PAD (Table 1). To
maximize therapeutic efficacy, biomaterials should
be engineered according to specific design criteria,
including material selection, mechanical properties,
chemical properties, and so on. Design parameters
and accompanying modifications are shown in
Figure 1. This review will highlight design criteria andive Medicine, University of California San Diego, La
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TABLE 1 Acellular Injectable Biomaterial Applications for MI and PAD
Material MI/PAD Material Form Biologics Delivered Modifications Ref. #
Alginate MI Hydrogel HGF, IGF-1; PDGF-BB, VEGF-A Conjugation with cell adhesion
peptides; sulfation;
copolymerization with fibrin
(7–16,61,65)
PAD Hydrogel; microspheres IGF-1, VEGF; HGF; VEGF-F; SDF-1 Combination with poly(d,l-lactide-
co-glycolide) microspheres;
sulfation; combination with
collagen hydrogel
(44,106,109,113)
Chitosan MI Hydrogel bFGF; FGF-2 Introduction of azide (60,70)
PAD Hydrogel FGF-2 Combination with lactose moieties
and a periodate-oxidized IO4
heparin solution
(100)
Collagen MI Hydrogel N/A N/A (20,22)
PAD Hydrogel; microsponges;
microspheres
SDF-1; bFGF; bFGF, HGF Combination with alginate
microspheres
(103,106,111)
Decellularized myocardial ECM MI Hydrogel N/A N/A (28,30)
Decellularized pericardial ECM MI Hydrogel bFGF; HGF N/A (67,68)
Decellularized skeletal muscle ECM PAD Hydrogel N/A N/A (85,93)
Decellularized small intestine
submucosa ECM
MI Particles; hydrogel N/A N/A (25,34)
Dextran MI Microparticles HGF Acetalated (69)
PAD Nanoparticles VEGF Copolymerization with gelatin (114)
Fibrin MI Hydrogel bFGF Delivery with heparin-conjugated
PLGA nanospheres;
copolymerization with alginate
(13,18,19,22,63)
PAD Hydrogel; particles FGF-2 Conjugation with heparin (91,92,115)
Fucoidan PAD Hydrogel FGF-2 N/A (110)
Gelatin MI Microspheres bFGF; IGF-1, VEGF N/A (59,62,64,66)
PAD Microspheres; hydrogel FGF-4; bFGF; FGF-2; G-CSF Crosslinking with poly-L-glutamic acid,
crosslinking with poly-L-lysine
(97,99,101,102,104,
105,107,108,112,116)
Hyaluronic acid MI Hydrogel rTIMP-3 Methacrylation; crosslinking with
hydroxyethyl methacrylate;
acrylation, crosslinking with PEG
tetra-thiol
(23,32,33,71)
Keratin MI Hydrogel N/A N/A (29)
Matrigel MI Hydrogel N/A N/A (22,26)
PEG based MI Hydrogel VEGF; HGF, VEGF; HGF,
IGF-1; EPO
Crosslinking with amide- succinimidyl
glutarate; crosslinking with
succinimidyl glutaramide or
amine; derivatization with
vinyl sulfone; copolymerization
with polycaprolactone;
copolymerization with poly
(d-valerolactone); functionalization
with cell adhesion peptides;
coupling with UPy units;
combination with a-cyclodextrin
and copolymerization with
polycaprolactone
(17,21,24,27,31,72–74)
Peptide nanofibers MI Hydrogel VEGF; IGF-1; FGF-2, PDGF-BB Biotinylation of peptides (76,80,82)
PLGA based MI Microparticles,
nanoparticles
NRG-1, FGF-1; VEGF; IGF-1 Copolymerization with
poly[(D,L-lactide-co-glycolide)-
co-PEG]
(75,77,78,83)
PAD Nanoparticles FGF-2 N/A (98)
PNIPAAm based MI Hydrogel bFGF Combination with dextran chains
and poly(ε-caprolactone)-2-
hydroxylethyl methacrylate;
copolymerization with acrylic acid
and hydroxyethyl methacrylate-
poly(trimethylene carbonate);
copolymerization with propylacrylic
acid and butyl acrylate
(35,36,79)
UPy MI Hydrogel HGF, IGF-1 N/A (81)
bFGF ¼ basic fibroblast growth factor; ECM ¼ extracellular matrix; EPO ¼ erythropoietin; FGF ¼ fibroblast growth factor; G-CSF ¼ granulocyte-colony stimulating factor; HGF ¼ hepatocyte growth factor;
IGF ¼ insulin-like growth factor; MI ¼ myocardial infarction; NRG ¼ neuregulin; PAD ¼ peripheral artery disease; PDGF-BB ¼ platelet-derived growth factor BB; PEG ¼ polyethylene glycol;
PLGA ¼ poly(lactic-co-glycolic acid); PNIPAAm ¼ poly(N-isopropylacrylamide); rTIMP ¼ recombinant tissue inhibitor of matrix metalloproteinase-3; SDF-1 ¼ stromal cell-derived factor;
UPy ¼ ureidopyrimidinone; VEGF ¼ vascular endothelial growth factor.
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FIGURE 1 Design Variables to Be Considered When Developing Biomaterial Applications for MI and PAD
To successfully translate biomaterials to the clinic, specific design criteria must be considered to ensure that the final product remains
biocompatible while maintaining its full therapeutic efficacy. Extensive engineering of a biomaterial can maximize therapeutic benefits, but
these benefits must counterbalance accompanied costs and manufacturing difficulties. MI ¼ myocardial infarction; miRNA ¼ microribonucleic
acid; PAD ¼ peripheral artery disease.
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215mechanisms of actions for biomaterial applications in
PAD and MI patients and will discuss the progress
toward engineering effective biomaterial-based ther-
apies. These biomaterial applications will include
material-alone approaches, as well the use of bio-
materials as delivery vehicles for acellular biologics
(Central Illustration).
DESIGNING ACELLULAR INJECTABLE
BIOMATERIAL THERAPIES FOR MI
BIOMATERIALS ALONE. In general, biomaterials
designed for MI have demonstrated capabilities to
prevent negative LV remodeling, including increasing
infarct wall thickness and decreasing LV volume,
fibrosis, and infarct size (7–36). Additionally, many
biomaterials also promote other beneficial processes
like neovascularization. Since the first papers
published in 2004 (18,19), studies in this area
have significantly increased; a detailed coverage
of individual studies can be found in other reviews
(37–39).
For treating MI, important design criteria include
material spread, delivery, and material selection,
which affects chemical, mechanical, and degradationproperties. Beginning with material selection, bio-
materials can be divided into 2 classes: natural and
synthetic biomaterials. Natural biomaterials can be
derived from biological sources like alginate from
brown algae (9,11,15,16), collagen from connective tis-
sue (20,22,40), or decellularized extracellular matrix
(ECM) isolated from various tissues and organs
(28,41,42). Several synthetic polymers like variations
of poly(N-isopropylacrylamide) (35,36) and syntheti-
cally modified naturally derived materials such as
methacrylated hyaluronic acid (HA) have also been
tested (23,32). For eventual translation into MI patients,
factors like biocompatibility, manufacturing ease, and
cost must be considered. For naturally derived bio-
materials, 2 main advantages include the ability to
mimic native biochemical cues and potentially more
cost-effective manufacturing by avoiding complex
chemical synthesis. However, naturally derived mate-
rials can suffer from batch-to-batch variability due to
variations in biological sources. With synthetic bio-
materials, the material properties can be customized
more extensively, and there are fewer issues with
limited availability of raw materials. Conversely, dis-
advantages include potential biocompatibility issues
and difficulty replicating the complex native tissue
FIGURE 2 Cellular Responses to Injected Biomaterials
Upon injection of a biomaterial, the resulting cellular responses can largely affect eventual tissue regeneration. Hematoxylin and eosin images are shown for (A) a
decellularized myocardial extracellular matrix hydrogel (3 days post-injection), (B) acetalated dextran microparticles (7 days post-injection), (C) a methacrylated
hyaluronic acid hydrogel (1 day post-injection), (D) a poly(N-isopropylacrylamide)-based synthetic hydrogel (8 weeks post-injection), and (E) an alginate hydrogel
(14 days post-injection). (F) Masson’s trichrome staining shows residual alginate in a heart section 5 weeks post-injection. All tissue sections are from the heart except
for (E), which is skeletal muscle. Black arrows, asterisks, and “G” denote the biomaterial. Reproduced with permission from Seif-Naraghi et al. (28), Suarez et al. (43),
Ifkovits et al. (23), Fujimoto et al. (35), Borselli et al. (44), and Yu et al. (16).
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vantages, most research for treating MI has utilized
naturally derived biomaterials or syntheticallymodified
derivatives (37–39).
Other factors to be considered for material selec-
tion include chemistry and mechanical properties,
which can affect important cellular processes upon
injection. These cellular responses, forming the
basis for 1 proposed mechanism of action, include
neovascularization, shifts in inflammatory/immune
cells, decreases in cell death, changes in fibroblast
activity (i.e. matrix production), and/or recruitment
and differentiation of stem or progenitor cells.
Figure 2 displays the cellular response of varying
biomaterials upon injection (16,23,28,35,43,44).
Although the exact material properties leading to
these outcomes are still unknown, chemical proper-
ties can be engineered accordingly, or biomaterials
with the necessary properties should be selected.
Naturally derived biomaterials, like collagen or
decellularized ECM, have adhesion proteins,
including fibronectin, fibrinogen, laminin, or
collagen, to promote cell attachment. Using collagen
and fibrin glue injections, neovascularization pro-
cesses were stimulated (19,22), while porcine-derived
myocardial ECM hydrogels promoted infiltration ofendothelial cells, smooth muscle cells, and progenitor
cells (30,41). However, for biomaterials lacking
adhesion peptides, cell adhesion peptide sequences,
like arginine-glycine-asparagine, can be added to
improve cell adhesion, as was done by Yu et al. (16)
with alginate. This modification resulted in signifi-
cantly increased arteriole density relative to
phosphate-buffered saline and unmodified alginate
control subjects after 5 weeks post-treatment in a rat
MI model.
Another mechanism of action focuses on the
mechanical support provided by biomaterial scaffolds,
which may reduce wall stress according to LaPlace’s
law. Mechanical properties are well known to affect
cell fate (45,46) and have been shown to affect out-
comes in the heart (23). However, recent studies sug-
gest that injectable materials in the heart
predominantly act through their bioactivity and/or cell
response rather than a mechanical support (27,47).
Moreover, many injected materials showing improve-
ments in cardiac function are weak hydrogels with
stiffnesses significantly lower than the myocardium,
likely providing minimal mechanical support. One
studymodulatingmechanical properties of aHA-based
hydrogel resulted in differences in infarct size (23),
showing that mechanical properties of a material are
FIGURE 3 Delivery Methods for Biomaterial-Based Applications in MI
When designing a biomaterial approach for MI, the importance of the delivery route is
often underestimated. (A) Intracoronary infusion via a balloon infusion catheter relies on
leaky acute MI vasculature for delivery, whereas (C) transendocardial injection via a
catheter requires specialized training. However, neither of these minimally invasive
methods requires an invasive surgery, unlike (B) direct epicardial injections.
Reproduced with permission from Stamm et al. (53).
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217indeed important; however, these results could be
related to the corresponding cellular response.
Although not typically a concern with naturally
derived injectable hydrogels, one should also ensure
that a material is not too stiff so that it negatively af-
fects diastolic function.
Similar to chemistry and mechanical properties,
degradation properties can be significantly affected
by poor material choice. Variables like the pH (which
is acidic in an acute infarct [48]), temperature, and
mechanical environment of the implanted biomate-
rial can also affect the degradation time. For most
biomaterials tested to date, degradation times
were inherent; however, it is possible to modify
degradation rate though modulating chemistry, con-
centration, crosslinker density, porosity, and hydro-
phobicity. Burdick et al. (49) investigated the effects
of HA macromer concentration, whereas Lee et al.
(50) demonstrated the effect of crosslinking on
degradation rates. Altogether, the inherent chemical,
mechanical, and degradation properties of the chosen
biomaterial can greatly influence the long-term ther-
apeutic efficacy.
One critical, but often overlooked, design criterion
is the delivery method for biomaterial therapies.
Although injectable biomaterial-alone approaches
and biomaterial patches (40,42,51) have gained
attention for their therapeutic benefits, injectable
versions have the advantage of a minimally invasive
delivery route (52). Current delivery approaches
include intracoronary infusion via a balloon infusion
catheter, direct epicardial injection with a single- or
double-barrel syringe, or transendocardial injection
via a catheter (Figure 3) (53). Epicardial injections
have the most control over delivery but often require
an invasive surgical procedure, which is likely to
complicate widespread use. Although the 2 remaining
methods are minimally invasive, they have disad-
vantages, including relying on leaky acute MI vascu-
lature for intracoronary delivery and needing
specialized training for transendocardial delivery.
Obviating the need for an invasive surgery with
general anesthesia has, however, resulted in the
majority of injectable therapeutics, including
biomaterials, being delivered via catheter-based
approaches in clinical trials. For catheter delivery,
the material must be hemocompatible given emboli-
zation risks since the material is injected into a cor-
onary with an infusion approach and is known to leak
into the LV chamber with transendocardial injections.
In addition, the material must be designed to have
appropriate gelation kinetics to travel through a long,
small-diameter catheter (typically 27-gauge) and gel
in the infarct, but not in the blood stream. The rapidgelation and/or lack of hemocompatibility have pre-
vented most injectable biomaterials from being
delivered with these more translationally relevant
methods. For instance, an alginate formulation that is
being studied in HF patients was not initially
designed for catheter delivery and, therefore, must be
delivered via an invasive surgical approach (7,12). In
particular, multiple injections required with trans-
endocardial injections create a unique design
constraint not common with other injectable bioma-
terial applications.
Upon injection, other variables, like material
spread, have also been studied to avoid dangerous
side effects like arrhythmias. A study by Suarez et al.
(31) looked at the effects of interstitial spread with
poly(ethylene glycol)-based hydrogels and did not
discover changes to action potential propagation with
high spreading materials. However, significant delays
as well as a reduction in gap junction density were
found with materials that were quick gelling and
formed a bolus, suggesting that they may be a po-
tential substrate for arrhythmias (31). This study was
only done in rats, though, and additional studies are
TABLE 2 Clinical Trials for Injectable Biomaterials in MI and PAD
Material
Product Name
(Identifier #) Trial Phase MI/PAD
Study Design
Results Ref. #Design Control Patient Population Delivery
Gelatin
microspheres
with bFGF
N/A N/A PAD Nonrandomized None Patients with CLI, no
option of medical
or surgical
treatment
(7 total)
Single intramuscular
injection (200 mg)
Significant
improvements in
6-min walk
distance, blood
perfusion,
transcutaneous
oxygen pressure,
and rest pain
scale compared
with pre-
treatment values
(112)
Alginate Algisyl-LVR
(NCT00847964)
I MI Nonrandomized None HF patients (9 total) Intramyocardial
injections during
cardiac bypass
surgery or valve
replacement/
repair (9–15
injections, 0.25–
0.35 ml each)
Improved LV function
and quality of life
(10)
Algisyl-LVR
(NCT01311791)
II
(AUGMENT-HF)
MI Randomized,
single-blind
Standard
medical
therapy
alone
HF patients,
approximately
one-half with
previous MI
(n ¼ 78)
Intramyocardial
injections via
limited left
thoracotomy
(10–19 injections,
0.3 ml each)
Significant increases
in peak VO2 levels
and 6-min walk
test distance, no
changes in EF, LV
end-diastolic
diameter, or LV
end-systolic
diameter
(7,12)
Alginate BL-1040
(NCT00557531)
I MI Nonrandomized None Experienced
moderate to large
MI, underwent
successful
primary PCI
(n ¼ 27)
Catheter-based
intracoronary
infusion (2 ml)
Preserved LVEDV
index, LVESV
index, and LVEF
(8)
IK-5001
(NCT01226563)
II
(PRESERVATION I)
MI Randomized,
double-
blind
Placebo
(saline)
Experienced large MI,
underwent
successful
primary PCI
(n ¼ 303)
Catheter-based
intracoronary
infusion (4 ml)
No differences in
terms of LVEDV
index
(14)
Decellularized
myocardial
ECM hydrogel
VentriGel
(NCT02305602)
I MI Nonrandomized None Experienced previous
MI, 60 days to 3
years since event
(18 patients
projected)
Transendocardial
delivery via
MyoStar catheter
Ongoing (28)
CLI ¼ critical limb ischemia; EF ¼ ejection fraction; HF ¼ heart failure; LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolic volume; PCI ¼ percutaneous
coronary intervention; other abbreviations as in Table 1.
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biomaterials.
By harnessing the potential of naturally derived
biomaterials, several studies have progressed into
clinical trials (Table 2). Using calcium crosslinked
alginate hydrogels, the PRESERVATION I (IK-5001 for
the Prevention of Remodeling of the Ventricle and
Congestive Heart Failure After Acute Myocardial
Infarction) trial (NCT01226563) included patients
who had experienced a large MI and underwent
successful primary PCI within 48 h of symptom onset,
whereas the AUGMENT-HF (A Randomized,
Controlled Study to Evaluate Algisyl-LVR as a Method
of Left Ventricular Augmentation for Heart Failure)
trial (NCT01311791) included HF patients, with
approximately one-half of the participants havingexperienced a previous MI. PRESERVATION I partic-
ipants received 4-ml infusions of either saline or the
alginate solution 2 to 5 days post-PCI into the
occluded artery via catheter-based intracoronary
infusion (14). Despite observing prevention and a
reversal of LV dilation and increased scar thickness in
a swine acute MI model (11) and conservation of the
LV end-diastolic volume index, LV end-systolic vol-
ume index, and ejection fraction (EF) with 2-ml in-
fusions of the alginate hydrogel in the Phase I trial
(8), no differences were seen between the treated
and control groups in terms of the LV end-diastolic
volume index after 6 months. It has been suggested
that this was a result of too little material being
utilized for larger infarcts, timing of treatment
administration, and/or the inability of the material to
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sions. Another significant possibility is that cells do
not adhere readily to alginate, and thus it has mini-
mal bioactivity, which could have resulted in a lack of
improvements. In the AUGMENT-HF trial, signifi-
cantly increased peak VO2 levels and 6-min walk test
distance were seen at 3, 6, and 12 months after
intervention via 10 to 19 0.3-ml intramyocardial in-
jections through a limited left thoracotomy approach
compared with standard medical therapy alone (7,12).
However, compared to improved LV function and
quality of life with alginate administration during
cardiac bypass surgery or valve replacement/repair in
phase I studies (10), no significant changes in the EF,
LV end-diastolic diameter, or LV end-systolic diam-
eter were seen in phase II. The latest biomaterial-
alone therapy to advance into clinical trials is based
on the preclinical studies done by Seif-Naraghi et al.
(28) with an injectable decellularized myocardial ECM
hydrogel in a porcine MI model. At 3 months post-
injection, pigs treated with the ECM hydrogel
showed an increase in global and regional cardiac
function compared with control animals. In addition,
the myocardial matrix hydrogel increased cardiac
muscle compared with noninjected and saline-
injected animals. Currently in a phase I clinical
trial (NCT02305602), VentriGel (Ventrix, Inc., San
Diego, California) is being delivered via trans-
endocardial injections with a MyoStar catheter (Bio-
sense Webster, Diamond Bar, California) in patients
who experienced a previous MI (60 days to 3 years
since the event).
Compared with other emerging therapeutics for
MI, biomaterials also represent a potentially more
promising approach in terms of translation and
commercialization (54). Biomaterial hydrogels allow
for more precise treatment since the material remains
localized upon injection unlike small molecule or
protein therapeutics, which rapidly diffuse away
from the injection site (55,56), or cell injections,
which also migrate and have poor survival (57,58).
Lastly, biomaterials alone represent a more cost-
effective option since incorporation of additional
therapeutics can dramatically increase expenses. By
incorporating and understanding some of the design
criteria described in the previous text, several
biomaterial-alone approaches have yielded positive
results, leading to a few clinical trials. To advance the
field and progress into greater numbers of clinical
trials, it is imperative that researchers consider these
design criteria from the beginning. It will also be
important to elucidate the mechanisms of action of
these materials, which will lead to improved material
generation.BIOMATERIALS AND GROWTH FACTORS. In addition to
utilizing biomaterial-alone approaches, codelivery
with additional acellular biologics, predominantly
growth factors, has been employed (Table 1) (59–83).
A major challenge for growth factor therapeutics has
been rapid diffusion upon delivery, but biomaterial
delivery vehicles can prolong the release rate and
improve localization by selecting or designing bio-
materials to elicit the desired release profile. Addi-
tionally, using biomaterials can decrease the costs of
incorporating growth factors since smaller quantities
are required. Generally, the material form, degrada-
tion properties, and chemistry are paramount for
enhancing rate of release and localization; therefore,
material selection and additional modifications must
be analyzed to identify the optimal delivery vehicle.
For physical and degradation properties, bio-
materials must retain and then gradually release
growth factors upon delivery. The microscale or
nanoscale architecture of hydrogels, microparticles,
or nanoparticles significantly contributes to this
tunable release (Figure 4) (29,67,78,84–86); results for
individual studies can be found in another review
(87). With hydrogels and particles, the architecture
provides small pores for slow growth factor release,
and gradual degradation of the material contributes
to a more complete release. Through the gelation of
hydrogels or targeted delivery with particles, growth
factors are localized to a region of interest and cannot
diffuse rapidly upon delivery. Additionally, regulated
delivery prevents systemic side effects due to un-
controlled diffusion, demonstrated by Lin et al. (82),
with significantly reduced vascular leakage resulting
from codelivery of high doses of vascular endothelial
growth factor (VEGF) with self-assembling peptide
nanofibers. Although a longer release may seem
favorable, this is not true for all growth factors. In
fact, complex processes, like angiogenesis, require
precise timing and order for the delivery of thera-
peutics (84,88). Suarez et al. (69) demonstrated this
importance with an engineered hepatocyte growth
factor (HGF) fragment diffusing at varying rates from
acetalated dextran microparticles in a rat MI model
due to different degradation profiles, showing that it
was most effective when delivered over 3 days
compared with 1.5 or 2.5 weeks.
Instead of solely relying on the architecture of the
biomaterial to control the retention and release, bio-
materials can also be modified to encourage binding
and retention of growth factors. This can be achieved
through the presence of sulfated glycosaminoglycans
or sulfation of a biomaterial to contribute to a
slower release profile. Binding of growth factors
can also yield higher therapeutic efficacy by
FIGURE 4 Structures of Biomaterials for MI and PAD Applications
Biomaterial structures dictate important parameters including degradation and controlled release of therapeutics. The architecture, shown by scanning electron
micrographs, varies among hydrogels, such as (A) keratin, (B) porcine-derived skeletal muscle extracellular matrix (ECM), (C) porcine-derived pericardial ECM,
(D) collagen, (E) alginate, or (F) fibrin. Additionally, hydrogel architecture differs from particles like (G) poly(lactic-co-glycolic acid) microparticles or (H) acetalated
dextran microparticles. Reproduced with permission from Shen et al. (29), DeQuach et al. (85), Seif-Naraghi et al. (67), Freeman et al. (84), Losi et al. (86),
Formiga et al. (78), and Suarez et al. (43). Abbreviations as in Figure 1.
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220increasing stability and activity, as was reviewed by
Zisch et al. (89) for the release of angiogenic growth
factors. Ruvinov et al. (65) also showed this with an
affinity-binding alginate biomaterial consisting of
insulin-like growth factor-1 and HGF bound by
alginate-sulfate interactions in a rat MI model. After
4 weeks, the fibrotic area was significantly reduced
and the relative scar thickness, blood vessel density,
and average individual blood vessel area were
significantly increased. With decellularized ECM
hydrogels, however, sulfation is unnecessary because
sulfated glycosaminoglycans are still present after
decellularization (90). In 2 studies by Seif-Naraghi
et al. (67) and Sonnenberg et al. (68), decellularized
pericardial ECM hydrogels were mixed with basic
fibroblast growth factor (bFGF) and an engineered
HGF fragment, respectively. Both studies showed
significantly increased arteriole density in animals
treated with the ECM hydrogels and growth factors
over growth factors delivered in saline, whereas
Sonnenberg et al. (68), also observed an increased
fractional area change.
Research conducted on growth factors encapsu-
lated in biomaterials for treating MI has made several
advances into large animal models. Liu et al. (64)utilized bFGF incorporated into gelatin micro-
spheres in a pig infarct model, which yielded in-
creases in EF and vascular density. Mentioned earlier,
Lin et al. (82) injected self-assembling peptide nano-
fibers mixed with VEGF into a porcine MI model and
saw improvements in fractional shortening and
capillary and arteriole density and a decrease in
infarct size. Finally, Koudstaal et al. (81) investigated
a combination of growth factors, insulin-like growth
factor-1 and HGF, incorporated into a synthetic
hydrogel known as ureidopyrimidinone. Diffusion of
the growth factors from the ureidopyrimidinone
hydrogel resulted in increased cardiac function,
capillary density, and cardiac progenitor cell migra-
tion in a porcine MI model. These recent advance-
ments have provided a strong foundation for growth
factor delivery in biomaterials, but translation into
the clinic has been limited, potentially due to the high
cost of incorporating growth factors.
DESIGNING ACELLULAR INJECTABLE
BIOMATERIAL THERAPIES FOR PAD
BIOMATERIALS ALONE. Current experimental treat-
ments for PAD, including stem cells and growth
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221factors, have not been entirely successful for many of
the same reasons as MI therapeutics. Consequently,
an effective, minimally invasive treatment that
improves perfusion and repairs ischemic tissue dam-
age is still needed. Biomaterial-alone therapies have
shown considerable promise for repairing ischemic
muscle by encouraging reperfusion and neo-
vascularization (85,91–93), but the success of these
biomaterials as a stand-alone approach for PAD lies in
satisfying particular design constraints (Table 1, Figure
1). Although many of the important design properties
are similar to those mentioned earlier for MI,
including material selection, physical properties, and
degradation properties, the design criteria vary for
PAD and may fluctuate depending on the disease
spectrum of the patient (i.e., intermittent claudication
vs. CLI).
Similar to MI, material selection is extremely
important for PAD to encourage perfusion restoration
and muscle regeneration. Each biomaterial must be
engineered or evaluated to promote cell infiltration
and proliferation/differentiation to treat both the
ischemia and muscle atrophy associated with PAD
(94). As such, the materials must allow for cell
adhesion and have appropriate pore size for cell
migration. Several preclinical studies have investi-
gated naturally derived biomaterials like fibrin (91,92)
and decellularized ECM hydrogels (85,93), but syn-
thetic biomaterials have yet to be studied in detail.
Fibrin is well known to encourage vascularization and
has likewise been shown in rabbit hindlimb ischemia
models to increase perfusion (91,92); however, only
ECM hydrogels have been evaluated for muscle repair
(93). Chekanov et al. (91) utilized a fibrin sealant and
observed significant increases in collateral vessel
development and the area occupied by capillaries
compared with no treatment or saline alone. Simi-
larly, fibrin particles used by Fan et al. (92) yielded
significantly augmented capillary density and perfu-
sion recovery compared with control subjects.
DeQuach et al. (85) utilized an injectable porcine-
derived skeletal muscle ECM hydrogel in a rat hind-
limb ischemia model and showed an increase not only
in vascular cells, but also in proliferating muscle cells
and muscle progenitor cells. Even after selecting a
naturally derived material, however, the source for
that material must still be chosen. With decellular-
ized ECM hydrogels, for example, the tissue source
can affect therapeutic outcomes. In a study con-
ducted by Ungerleider et al. (93), 2 different decellu-
larized ECM hydrogels, a porcine-derived skeletal
muscle ECM and human umbilical cord ECM, were
assessed in a rat hindlimb ischemia model. Although
improvements in perfusion were seen for bothhydrogels, the muscles injected with the skeletal
muscle ECM hydrogel resembled the healthy
morphology more closely than those injected with the
human umbilical cord matrix, suggesting that tissue-
specific cues may be important for regeneration.
The last 2 design criteria to be discussed for a
biomaterial-alone approach in PAD are degradation
properties and delivery. The main factor to be
considered for degradation properties is whether the
biomaterial will yield sufficient therapeutic im-
provements before it completely degrades. Because
PAD most often affects the lower limbs, the
mechanical environment caused by a load-bearing
region can cause biomaterials to degrade more
quickly. As a result, appropriate animal models must
be used to generate results that are representative of
the human mechanical environment. For delivery of
these therapeutics, direct intramuscular injections
should be utilized (ideally #26-gauge for patients);
however, the number and timing of these injections
must be determined. Due to the large surface area of
the lower limbs, multiple injections of the bio-
materials will be necessary. Results from small animal
studies can provide insight for the appropriate
concentration and required volume of injections, but
these results must then be scaled up for larger
animals and clinical studies. To date, limited work
has been performed on developing a suitable large
animal model, although a few recent studies suggest
that this may be forthcoming (95,96). Overall, there
is still a great deal of research to be done for
biomaterial- alone approaches in PAD; however, it is a
promising approach that should be pursued.
BIOMATERIALS AND GROWTH FACTORS. Although
biomaterial-alone approaches have not been exten-
sively investigated for PAD, biomaterials have been
utilized to deliver growth factors, as shown in Table 1
(44,97–116). To maximize therapeutic efficacy of a
biomaterial and growth factor complex, similar
design criteria to MI should be applied, including
selecting or engineering materials based on physical
form, chemistry, and degradation properties. Physical
form, such as selecting particles as opposed to
hydrogels, can alter the delivery method due to the
ability to engineer particles for targeting. For chemi-
cal properties, modifications like binding moieties for
growth factors, such as sulfate groups, can be added
to encourage longer retention. Lastly, degradation
plays an equally important role in controlling reten-
tion and release since rapid degradation will lead to a
similar release rate for the therapeutic payload.
By incorporating these design principles,
researchers have advanced some therapies into
Hernandez and Christman J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 2 , 2 0 1 7
Injectable Biomaterials for PAD and MI A P R I L 2 0 1 7 : 2 1 2 – 2 6
222pre-clinical studies with rabbits and larger animal
models and even 1 clinical trial. An early study
conducted by Kasahara et al. (104) utilized gelatin
microparticles to deliver fibroblast growth factor
(FGF)-4 in a rabbit hindlimb ischemia model. Under
vasodilatory conditions, the perfusion levels and
angiographic scores were significantly higher in the
gelatin/FGF-4 complex compared with gelatin or
FGF-4 alone. In another study by Doi et al. (99), gelatin
hydrogels encapsulated with bFGF were injected
intramuscularly in Japanese white rabbits 2 weeks
post-hindlimb ischemia surgery. Animals treated with
the gelatin and bFGF hydrogel had significantly higher
perfusion levels and vascular density compared
with no treatment or gelatin alone at 4 weeks post-
injection. A large animal study performed in mongrel
dogs by Zhao et al. (116) studied bFGF encapsulated in
gelatin microspheres. Significantly higher capillary
densities and numbers of mature vessels were
observed with the gelatin microspheres and bFGF-
treated group relative to bFGF alone and empty mi-
crospheres. The final study to be mentioned includes
the findings of a phase I to IIa clinical trial (Table 2). In
a rabbit hindlimb ischemia model, Hirose et al. (101)
injected gelatin hydrogel microspheres containing
bFGF and saw increased perfusion, capillary density,
and collateral vessel development compared with a no
treatment control group. This led to an investigation
by Marui et al. (112) in which biodegradable gelatin
hydrogels loaded with bFGF were administered with a
single intramuscular injection in patients with CLI; no
controls were used for this study. At 4 and 24 weeks
post-treatment, improvements were seen in the
perfusion compared with values prior to treatment. By
utilizing biomaterials as delivery vehicles, the growth
factor release can be precisely controlled, and bio-
materials can prevent degradation of growth factors to
fully harness their therapeutic potential.
DESIGNING BIOMATERIALS AS DELIVERY
VEHICLES FOR EMERGING THERAPEUTICS
Although numerous studies presented in this review
demonstrate the efficacy of utilizing biomaterials
alone or a combination of growth factors and bio-
materials for treating MI and PAD, growth factors are
not the only acellular therapeutic that should be
considered for biomaterial-based therapies. Biologics
like erythropoietin and recombinant tissue inhibitor of
matrix metalloproteinase-3 have been studied (71,73),
yet emerging therapeutics, such as exosomes or
microribonucleic acids (miRNAs), may also enhance
the beneficial properties of biomaterials, while avoid-
ing obstacles plaguing cellular-based treatments.Previous studies investigated the efficacy of these
therapeutics in MI (117–124) and PAD preclinical
models (117,125–129), but limited research has been
conducted to optimize delivery. For exosomes,
microvesicles, and miRNAs, maximized therapeutic
efficiency has been hindered by poor retention upon
injection. Because these therapeutics are typically
injected alone, they rapidly diffuse from the injection
site, similar to growth factors, therefore leading to
minimal improvements in the targeted region. One
study by Hinkel et al. (123) revealed the effect of
catheter-based delivery compared with systemic de-
livery with antagomir-92a in a porcineMImodel. Using
a regional delivery approach, decreased infarct size
and apoptosis were seen, and EF was improved
compared with the systemic delivery.
This study emphasizes the importance of local
delivery, but utilizing a biomaterial as a delivery
vehicle is likely to further improve results. Because
miRNAs are quickly degraded after injection due to
the large amount of RNases circulating throughout
the body, biomaterials can provide a shielded envi-
ronment to maximize therapeutic effects. Addition-
ally, the controlled release provided by biomaterials
can also contribute to improved efficacy. Based on the
current advancements in biomaterial-based thera-
pies, many of the design principles discussed earlier
could overcome these obstacles.
The physical form and chemistry of a biomaterial
can significantly contribute to slower release kinetics
in addition to providing a protected environment from
degradation. By changing the physical form of the
biomaterial, the release can be tuned for the specific
payload, and targeting can also be incorporated with
particles. Additionally, altering the biomaterial’s
concentration often leads to changes in pore size,
which can be utilized to change the release profile.
The same microscale or nanoscale architecture being
modified for desired release kinetics can also be used
to protect the payload from degradation. In terms of
the chemistry, modifications can be made to allow for
better retention of additional therapeutics or release
only upon cell infiltration.
Although no biomaterial-based therapies have
been published for microvesicle or miRNA delivery in
MI or PAD, there are a few studies related to other
applications, which validate the use of biomaterials
for the delivery of these newer therapeutics. For bone
repair, a miR-29a inhibitor, intended to increase ECM
deposition, was delivered with gelatin nanofibers
(130). The investigators demonstrated the feasibility
of this approach, as well as efficacy in terms of a slow
release profile and sustained bioactivity of the miRNA
inhibitor once released compared with a scrambled
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223miRNA control. The Burdick lab has also begun
investigating a hydrogel system for small interfering
ribonucleic acid delivery (131), but further studies are
still ongoing. Therefore, this represents a promising
area of research for improving the delivery of the next
generation of therapeutics and should be explored for
MI and PAD.
FINDING THE OPTIMAL THERAPY
FOR MI AND PAD PATIENTS:
BALANCING THERAPEUTIC POTENTIAL
AND COMMERCIALIZATION CHALLENGES
Extensive research has validated the use of acellular
biomaterials, but difficulties must still be overcome
before implementation into the clinic. When consid-
ering incorporation of additional factors, an acellular
approach is optimal for multiple reasons. Including
cells dramatically reduces shelf life due to instability
and significantly increases manufacturing expenses
for a large-scale setting. The addition of growth fac-
tors encompasses many of these same issues,
including reduced shelf life and high cost, but new
manufacturing methods are being studied to over-
come these obstacles. For example, Cochran and
colleagues (68,132) have developed an engineered
HGF fragment with increased stability and lower cost
of manufacturing, while maintaining its therapeutic
effects. With new methods being optimized for
growth factor delivery, these lower-cost options
could result in more feasible biomaterial-based
treatments for MI and PAD patients.
As discussed earlier, biomaterials may also be
delivered alone and have produced significant im-
provements in animal models of MI and PAD. From
a manufacturing perspective, a biomaterial-alone
approach is the preferred method, as the increased
costs and manufacturing time associated with addi-
tional therapeutics are negated. However, several
studies previously mentioned suggest that acombinatorial approach may be more effective.
Although current growth factor therapies may not be
ideal for eventual translation to the clinic, due to
difficult and expensive manufacturing, less expen-
sive, engineered growth factors, like the one
mentioned previously, or other therapeutics may
augment the benefits of injectable biomaterials. The
studies utilizing microvesicles, exosomes, or miRNAs
alone have also demonstrated substantial therapeutic
efficacy in MI and PAD animal models, but more
research must be done to optimize the delivery of
these factors. In conclusion, research must be con-
ducted to investigate the delivery of additional ther-
apeutics with biomaterials, but the added therapeutic
efficacy must outweigh the additional costs.
CONCLUSIONS
Acellular biomaterial-based therapies may be a solu-
tion for many patients experiencing MI and PAD. By
harnessing the ability to engineer these biomaterials
and employing the minimally invasive nature of
many of these therapies, patients may soon receive
treatments designed to stimulate tissue regeneration
and improved muscle function. Although further
research must be conducted to develop optimal
biomaterial strategies, and manufacturing expenses
must be carefully considered, the field is rapidly
progressing toward identifying new treatments for
MI and PAD patients.
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